University Hospital Tuebingen
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1388-01-01
- Employees
- -
- Market Cap
- -
Open Label Trial of Utility of Cryobiopsy in the Multidisciplinary Diagnosis of Idiopathic Interstitial Lung Disease
Not Applicable
- Conditions
- Interstitial Lung Disease
- Interventions
- Procedure: Lung biopsy
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 100
- Registration Number
- NCT02563730
- Locations
- 🇩🇪
Ruhrlandklinik, Essen, Germany
🇩🇪Thoraxklinik, Heidelberg, Germany
🇩🇪University Hospital Tuebingen, Tuebingen, Germany
Kids Obesity Prevention Program - Study (KOP)
Not Applicable
Completed
- Conditions
- ObesityChild
- Interventions
- Other: The serious game KOP
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 60
- Registration Number
- NCT02551978
Metabolic Effects of Choline and Docosahexaenoic Acid Supplementation in Preterm Infants
Not Applicable
Completed
- Conditions
- Infant, Premature
- Interventions
- Dietary Supplement: DHA supplementationDietary Supplement: choline supplementationDietary Supplement: standard nutrition
- First Posted Date
- 2015-07-28
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 24
- Registration Number
- NCT02509728
- Locations
- 🇩🇪
University Hospital of Tuebingen, Tuebingen, Germany
Adjuvant Psychotherapy for Relapse Prevention in Early Adulthood (< 35 yr.) of Bipolar Disorder
Not Applicable
Completed
- Conditions
- Bipolar Disorder
- Interventions
- Behavioral: SEKT - Cognitive-Behavioral-EmotionalBehavioral: FEST - Clinical Supportive Educational
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 318
- Registration Number
- NCT02506322
- Locations
- 🇩🇪
Eberhard Karls University, Tuebingen, Germany
Influence of Central Nervous Insulin Action on Insulin Sensitivity of Peripheral Organs in Lean Versus Overweight Humans
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 21
- Registration Number
- NCT02468999
- Locations
- 🇩🇪
University of Tuebingen, Department of Internal Medicine IV, Tübingen, Germany
Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy
Phase 1
- Conditions
- Recurrent Prostate Cancer
- Interventions
- Biological: Peptide vaccineDrug: Montanide ISA-51Procedure: local hyperthermiaDrug: Granulocyte macrophage colony stimulating factor (GM-CSF)Drug: mRNADrug: Protamin
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 36
- Registration Number
- NCT02452307
Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 22
- Registration Number
- NCT02452294
- Locations
- 🇩🇪
Department of Dermatology, University Hospital, Tuebingen, Germany
🇩🇪Department of Dermatology, University Hopsital, Dresden, Germany
Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)
Not Applicable
Completed
- Conditions
- Melanoma
- Interventions
- Procedure: Clinical Monitoring (Palpation and node ultrasound)Procedure: Completion Lymphadenectomy
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 483
- Registration Number
- NCT02434107
- Locations
- 🇩🇪
Städtische Kliniken Darmstadt, Darmstadt, Germany
🇩🇪Ludwig-Maximilians-Universität, Munich, Germany
🇩🇪Universitätsklinkum Münster, Münster, Germany
Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides
Phase 1
- Conditions
- Renal Cell CancerAdvanced Renal Cell Cancer
- Interventions
- Biological: peptide vaccineDrug: Granulocyte Macrophage Colony Stimulating FactorDrug: Montanide ISA-51
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 40
- Registration Number
- NCT02429440
Pre-meal Planning and Expected Satiety
- Conditions
- Adiposity
- First Posted Date
- 2015-04-27
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 60
- Registration Number
- NCT02427152
- Locations
- 🇩🇪
University Clinic of Tuebingen, fMEG Center, Tuebingen, Germany
© Copyright 2025. All Rights Reserved by MedPath